| Literature DB >> 16283207 |
Abstract
Buprenorphine has been widely used and studied for over 20 years and has been shown to be an effective opioid analgesic. Some years ago a buprenorphine formulation for transdermal therapy of chronic cancer-related and non-cancer-related pain became available. We report the case of a woman who received a lower dosed transdermal buprenorphine patch (3/5 of a 35 microg/h patch corresponding to release of 21 microg/h buprenorphine) during pregnancy without any complication for herself or the child. The patient has now being using the transdermal system for more than 2 years and has reported continuous excellent pain relief. The buprenorphine patch was well tolerated and produced no effect on vigilance over the whole period of administration.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16283207 DOI: 10.1007/s00482-005-0445-4
Source DB: PubMed Journal: Schmerz ISSN: 0932-433X Impact factor: 1.107